Clinical trials: Soft-tissue Sarcomas
Kaposi Sarcoma
Propranolol for the Treatment of Kaposi Sarcoma in Adults
Kaposi sarcoma (KS) lesions are initiated by endothelial cells infected with KS herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8).
- Trial name
- NCT06445166
- Testing
- Propranolol Hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Kaposi s Sarcoma (KS)
Studies of Human Herpesvirus 8 and Kaposi's Sarcoma in Sicily
A series of studies will be conducted in Sicily by a collaborative team from the U.S. National Cancer Institute and the University of Palermo to better understand the prevalence and risk factors for the newly discovered human…
- Trial name
- NCT00339937
- Where
- Italy
- Volunteers
- 4,622 people
- Sponsor
- National Cancer Institute (NCI)
Breast Carcinoma, Healthy Subject
Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer, Sarcoma, Skin Cancer, or Soft Tissue Malignancy and Healthy Volunteers
This pilot trial studies how well photoacoustic imaging works in diagnosing changes in tumors in participants with breast cancer, sarcoma, skin cancer, or soft tissue malignancy and healthy volunteers.
- Conditions
- Breast Carcinoma, Healthy Subject, Malignant Soft Tissue Neoplasm, Sarcoma
- Trial name
- NCT03630601
- Testing
- Photoacoustic Imaging
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Unresectable or Metastatic Bone and Soft Tissue Sarcoma
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma
This is a multicenter, open-label, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with unresectable or metastatic bone and soft tissue sarcoma who has failed at least one…
- Trial name
- NCT04900766
- Testing
- Mitoxantrone Hydrochloride Liposome Injection
- Where
- China
- Volunteers
- 31 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Solid Tumours, Sarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which…
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
- Trial name
- INVOKE (NCT06789172)
- Testing
- OKN4395, Pembrolizumab, Fasting
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Epkin
Advanced Melanoma, Melanoma Metastatic
NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
A single center, dose escalaion, Phase I clinical trial to demonstrate safety and efficacy of LauT-1, autologous "New York Esophageal Squamous Cell Carcinoma-1 T-Cell Receptor (NY-ESO-1 TCR)-directed T cells in combination with…
- Conditions
- Advanced Melanoma, Melanoma Metastatic, Sarcoma
- Trial name
- LauT1 (NCT06889766)
- Testing
- NY-ESO-1 TCR redirected autologous T cell product, Low-dose irradiation, Non-myeloablative lymphodepleting chemotherapy
- Where
- 2 sites in Switzerland
- Volunteers
- 9 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
SMARCB1-Deficient Malignancies, Epithelioid Sarcoma
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
To find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).
- Conditions
- SMARCB1-Deficient Malignancies, Epithelioid Sarcoma, Renal Medullary Carcinoma
- Trial name
- NCT06444880
- Testing
- Ubamatamab, Cemiplimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Sarcoma
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
This study is the first time that a new experimental drug called [18F]-SKI-249380 is being used in people. [18F]-SKI-249380 is not a therapeutic drug.
- Conditions
- Carcinoma, Sarcoma, Myeloma, Lymphoma
- Trial name
- NCT01916135
- Testing
- [18F]-SKI-249380, PET/CT scan, Blood draws
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Retinoblastoma, Clear Cell Sarcoma
Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
This is a Phase I trial with new experimental drugs such as simvastatin in combination with topotecan and cyclophosphamide in the hopes of finding a drug that may work against tumors that have come back or that have not responded…
- Conditions
- Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Rhabdoid Tumor
- Trial name
- AflacST1402 (NCT02390843)
- Testing
- Simvastatin, Cyclophosphamide, Topotecan
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Emory University
Angiosarcoma
Identification, Molecular Epidemiology Angiosarcoma of the Liver France
The purpose of this study is to test the feasibility of identifying incident cases of angiosarcoma of the liver from the network NetSarc.
- Trial name
- ANGIHE (NCT01786889)
- Testing
- blood and urine, Questionnaire, Telephone interview
- Where
- 12 sites in France
- Volunteers
- 9 people
- Sponsor
- Centre Oscar Lambret
Sarcoma, Soft Tissue
Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma
This is a prospective, multicentric, randomized, open label Phase II trial investigating whether the oral angiogenesis inhibitor nintedanib, as compared to the intravenous cytotoxic compound ifosfamide, given for patients with…
- Trial name
- ANITA (NCT02808247)
- Testing
- Nintedanib, Ifosfamide
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 80 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Kaposi's Sarcoma
Risk Factors for Non-HIV-Related Kaposi s Sarcoma
This study will try to identify risk factors for Kaposi s sarcoma, a rare skin cancer, and to understand the role of the KSHV virus in development of the disease.
- Trial name
- NCT00339326
- Where
- Italy
- Volunteers
- 1,383 people
- Sponsor
- National Cancer Institute (NCI)
Soft Tissue Sarcoma
Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)
This is a Phase 2, single-arm, open-label study in patients with advanced or unresectable soft tissue sarcoma.
- Trial name
- NCT05497843
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Soft Tissue Sarcoma, High Risk of Recurrence
Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma
The purpose of this study is to evaluate the efficacy and safety of dose reduced postoperative radiotherapy combined with Anlotinib for patients of soft tissue sarcoma
- Conditions
- Soft Tissue Sarcoma, High Risk of Recurrence, Anlotinib, Radiotherapy
- Trial name
- NCT05602415
- Testing
- Anlotinib, Radiotherapy, Surgery
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Ruijin Hospital
Adult Soft Tissue Sarcoma
NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity
RATIONALE: Radiation therapy given before surgery of soft tissue sarcoma decreases the size of the tumor mass and the presence of malignant cells in its peripheral region.
- Trial name
- NCT01433068
- Testing
- NBTXR3
- Where
- 2 sites in France
- Volunteers
- 22 people
- Sponsor
- Nanobiotix
Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer
A Survivorship Care Plan for Gynaecological Cancer Patients
After treatment women surviving gynaecological cancer may experience lateeffects and longterm challenges specific to their disease and treatment resulting in functional deficits and a reduction in societal integration (Yabroff et…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer, Endometrial Cancer, Esophageal Cancer
- Trial name
- NCT01582906
- Where
- United Kingdom
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Osteosarcoma in Children
Integrated Clinical-radiological Analysis of Hypoxia Markers in Pediatric Osteosarcomas
The aim of this pilot study is therefore to retrospectively measure the volume and percentage of necrosis on diagnostic MRI in T1 sequence and in parallel to study the expression of immunohistochemical markers of hypoxia (HIF-1α…
- Trial name
- SARCOMAS (NCT05107843)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Clear Cell Sarcoma
QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma
This is a phase 2 study that will assess the efficacy of AMG 337 in subjects with advanced or metastatic clear cell sarcoma that contains the EWSR1-ATF1 gene fusion.
- Trial name
- NCT03132155
- Testing
- AMG 337
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- NantPharma, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.